Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma
about
Risk based neoadjuvant chemotherapy in muscle invasive bladder cancerIntegrative clinical genomics of advanced prostate cancer.Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial CarcinomaInvasive Bladder Cancer: Genomic Insights and Therapeutic PromiseComprehensive assessment of cancer missense mutation clustering in protein structuresSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Systemic therapy for bladder cancer finally comes into a new age.The genomic landscape of testicular germ cell tumours: from susceptibility to treatment.Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.DNA Repair Pathway Alterations in Bladder Cancer.The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.Molecular biology of bladder cancer.Novel molecular targets for urothelial carcinomaA unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistanceThe safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experienceIdentification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial CarcinomaGemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.Urothelial carcinoma management in elderly or unfit patients.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerCollaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.Precision medicine for advanced prostate cancer.An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder CancerMeta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical UseSEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Circulating Biomarkers in Bladder Cancer.New discoveries in the molecular landscape of bladder cancer.Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancersNew advances in genitourinary cancer: evidence gathered in 2014.Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancerDose dense MVAC prior to radical cystectomy: a real-world experience.ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder CancerDNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.
P2860
Q26773664-5C157B87-73AD-4D35-9BE5-6D95B36C7320Q27853170-5CFB6FA2-C258-4C5E-8B6B-3DC1A3B5E3C4Q28084715-0D94CA66-0983-4E8C-8C56-BA5022597F8BQ28088334-7094C49E-4641-4688-A07A-9AE2DA23A032Q28606437-6B5EBF4A-4453-4902-A9FC-47707ACFFA63Q30240816-C36862F4-F522-4575-AEA5-BC07ADF10787Q30249047-BF98D57B-D16C-462E-8EAD-B7CE9DA6CC86Q30249650-F43F132B-D0B1-4642-B9D2-F8F55C70FF49Q33426694-3C61E3B2-3583-4305-826D-0919F234BFB4Q33607945-8E94D816-FD23-4484-B178-77CF98126E07Q33886353-576AEAA2-5BE8-40B6-90B4-98D385FE6578Q35266400-9342777C-97C3-46A7-B21B-F5CE1B429D9BQ35527068-7AC76114-3AC2-449B-B41B-4318BB086ED7Q35559721-3C027FDC-7EEB-444B-8186-70BCA7E6FE9CQ35586693-3ADC88BE-AB01-4EA9-BE8E-B6431916EDCAQ35731224-AEEFC081-F0F8-4317-B617-0C81D0B2EBE6Q35866471-3727724B-3ED5-4C53-82E5-1D02AE3AF737Q36328010-7F422DA6-5162-4727-83C7-6AB8A7D43646Q36608587-60847398-55C9-4D89-B9EE-92188BC3134FQ37012561-429CB563-1E29-4520-AA03-8ABA77E05890Q37030514-B7F78E9B-195D-481C-9AED-98394213E5EFQ37053820-C9B6713B-28A5-44DA-90D1-C97CA0E92623Q37053881-B8ED594E-DE40-4E87-A3DB-6D4B254BDC6DQ37074346-8D93879B-7048-48A5-A830-CEB4DE54F462Q37114034-5D0B5EC2-314F-4F81-8859-81F3060C7209Q37290684-3038F50A-8140-495F-8385-A2886A670DF6Q37363521-88A572DE-11E7-4893-8F97-3BF89A5DE8BCQ37475193-405073E5-22A2-4BC4-8DC0-4CF2EA4B5450Q37530401-300DB685-B38D-4CF4-9E86-0A07CA39D7FFQ37578747-8C06FFD8-7383-4CA8-A295-AC4BB8B3108BQ38259678-6ACC0295-B177-4503-9506-1AAAA20898ABQ38557894-CCE7F182-02DA-4420-9EE6-7516C29F029DQ38663576-F1257B10-2991-4BBA-A140-0D8629358624Q38720755-223C9B76-5296-46F7-B1CF-D3BD5D9B3F21Q38721568-319E253A-1E89-4533-BE6F-725154A860A9Q38764205-81B46932-08A3-4DF3-A26A-919EF03B741EQ38827251-1ACE7570-AAD9-41F6-958A-F8301E76EFA5Q38852690-BB08C690-320D-4679-A395-3F0B5D248BCDQ38862963-AF156DEF-1CF7-4DE5-8392-A0B794993A08Q38906407-927A7756-E1D8-4BD5-925A-347718B2ADD3
P2860
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma
@ast
Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma
@en
Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma
@nl
type
label
Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma
@ast
Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma
@en
Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma
@nl
prefLabel
Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma
@ast
Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma
@en
Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma
@nl
P2093
P2860
P50
P1433
P1476
Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma
@en
P2093
Alan D'Andrea
David B Solit
Dean F Bajorin
Deborah Farlow
Eliezer M Van Allen
Elizabeth A Guancial
P2860
P304
P356
10.1158/2159-8290.CD-14-0623
P407
P50
P577
2014-08-05T00:00:00Z